Shanghai Hile Bio-Technology Co., Ltd.

603718

CNE1000022T4

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
8.13 ^CNY	-0.73%		+6.00%	-24.09%

2023	Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	CI
2023	Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index	CI

Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Shanghai Hile Bio-Technology Co., Ltd.

Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-30	CI
Shanghai Hile Bio-Technology Co., Ltd.(XSSC:603718) added to S&P Global BMI Index	23-09-18	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Shanghai Zhizhuo Enterprise Management Consulting Co., Ltd. agreed to acquire Shanghai Caiyin Biotechnology Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for CNY 2 million.	23-04-11	CI
Shandong Sinder Technology Co., Ltd agreed to acquire Shandong Hile Biological Products Co., Ltd. from Shanghai Hile Bio-Technology Co., Ltd. for approximately CNY 110 million.	23-04-11	CI
Shanghai Hile Bio-Technology Plans to Sell Biological Products Unit	23-04-11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-11	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Shandong Hile Biological Products Co., Ltd. announced that it has received CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	22-09-29	CI
Shandong Hile Biological Products Co., Ltd. announced that it expects to receive CNY 140 million in funding from Shanghai Hile Bio-Technology Co., Ltd.	22-08-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
WuXi Vaccines Inc. announced that it expects to receive $136 million in funding from Shanghai Hile Bio-Technology Co., Ltd., WuXi Biologics Inc.	21-05-12	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it has received CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	21-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. completed the acquisition of 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A.	21-04-28	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-23	CI
WuXi Biologics Cayman : , Shanghai Hile to Restructure Vaccine JV	21-04-02	MT
Shanghai Hile Bio-Technology Co., Ltd. intends to acquire 40% stake in Yangling Jinhai Biotechnology Co., Ltd. from Biogenesis Bago S.A. and Biogénesis Bagó Uruguay S.A. for CNY 56 million.	21-03-16	CI
Yangling Jinhai Biotechnology Co., Ltd. announced that it expects to receive CNY 85 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	21-03-14	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020	20-10-27	CI
Shanghai Hile Bio-Technology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	20-08-30	CI
Hangzhou Shuchen Biotechnology Co., Ltd. announced that it expects to receive CNY 46.75 million in funding from Shanghai Hile Bio-Technology Co., Ltd., Shanghai Runling Investment Partnership	20-08-11	CI

Chart Shanghai Hile Bio-Technology Co., Ltd.

Duration

Period

Chart Shanghai Hile Bio-Technology Co., Ltd.

More charts

SHANGHAI HILE BIO-TECHNOLOGY CO., LTD. is principally engaged in the research & development, production and sales of veterinary biological products. The Companyâs products mainly include escherichia coli (K88 and K99) gene modified vaccines for piglets, inactivated; porcine reproductive and respiratory syndrome vaccines, live and swine infectious atrophic rhinitis vaccines, inactivated; newcastle disease mild vaccines, living; newcastle disease, infectious bronchitis, egg drop syndromeâ76 vaccines, inactivated and infectious bronchitis vaccines, living, among others. The Company distributes its products mainly in China.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Sector Veterinary Drugs

	1st Jan change	Capi.
SHANGHAI HILE BIO-TECHNOLOGY CO., LTD.	-24.09%	738M
ZOETIS INC.	-19.73%	72.39B
ELANCO ANIMAL HEALTH INCORPORATED	-11.01%	6.54B
BLUESTAR ADISSEO COMPANY	+15.88%	3.43B
VIRBAC	-2.92%	3.12B
VIMIAN GROUP AB	-0.68%	1.4B
JINYU BIO-TECHNOLOGY CO., LTD.	-17.27%	1.34B
VETOQUINOL SA	-2.73%	1.26B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD.	-28.16%	1.2B
WUHAN KEQIAN BIOLOGY CO.,LTD	-14.67%	1.12B